CN1480191A - Prophylaxis medication for treating pneumonia, bronchitis, pharyngitis and upper respiratory tract infection as well as its preparing method - Google Patents
Prophylaxis medication for treating pneumonia, bronchitis, pharyngitis and upper respiratory tract infection as well as its preparing method Download PDFInfo
- Publication number
- CN1480191A CN1480191A CNA031397697A CN03139769A CN1480191A CN 1480191 A CN1480191 A CN 1480191A CN A031397697 A CNA031397697 A CN A031397697A CN 03139769 A CN03139769 A CN 03139769A CN 1480191 A CN1480191 A CN 1480191A
- Authority
- CN
- China
- Prior art keywords
- radix
- bronchitis
- pharyngitis
- respiratory tract
- upper respiratory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 26
- 206010006451 bronchitis Diseases 0.000 title claims abstract description 21
- 206010057190 Respiratory tract infections Diseases 0.000 title claims abstract description 20
- 206010046306 Upper respiratory tract infection Diseases 0.000 title claims abstract description 20
- 201000007100 Pharyngitis Diseases 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title description 13
- 238000000034 method Methods 0.000 title description 4
- 238000011321 prophylaxis Methods 0.000 title 1
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 241000207929 Scutellaria Species 0.000 claims abstract description 7
- 239000003826 tablet Substances 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 241000628997 Flos Species 0.000 claims description 13
- 239000010231 banlangen Substances 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000004821 distillation Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000000341 volatile oil Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000605447 Anemarrhena Species 0.000 claims description 6
- 241000555712 Forsythia Species 0.000 claims description 6
- 241000202807 Glycyrrhiza Species 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 230000008901 benefit Effects 0.000 abstract description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000555682 Forsythia x intermedia Species 0.000 abstract 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 19
- 210000004072 lung Anatomy 0.000 description 19
- 206010011224 Cough Diseases 0.000 description 14
- 241000700605 Viruses Species 0.000 description 13
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 11
- 229940100050 virazole Drugs 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 206010035737 Pneumonia viral Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 241000712461 unidentified influenza virus Species 0.000 description 7
- 208000009421 viral pneumonia Diseases 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 241000725643 Respiratory syncytial virus Species 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000001088 anti-asthma Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001092500 Photinia x fraseri Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001660 histamine phosphate Drugs 0.000 description 1
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 210000003454 tympanic membrane Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine in the form of oral liquid, capsule, or tablet for preventing and treating pneumonia, bronchitis, pharyngitis, and upper respiratory tract infection is prepared from 11 Chinese-medicinal materials including honeysuckle flower, forsythia fruit, scutellaria root, liquorice root, etc. Its advantage is high curative effect.
Description
Affiliated technical field
The present invention relates to the medicine of a kind of prevention and treatment pneumonia, bronchitis, pharyngitis and upper respiratory tract infection, is the Chinese patent medicine of feedstock production with the Chinese herbal medicine specifically, the invention still further relates to the preparation method of this medicine.
Background technology
Pneumonia is a commonly encountered diseases, and China has 2,500,000 routine pneumonia to take place every year approximately, and 12.5 ten thousand people occupy the 5th because of pneumonia death in the various deadly causes of disease.When the low person of its middle-aged and elderly people and body's immunity was occurred together pneumonia, case fatality rate was high especially.Pneumonia is the inflammation of pulmonary parenchyma, can be caused by multiple pathogen, as antibacterial, fungus, virus, parasite or lonizing radiation, chemistry, irritated factor.In 2～3 weeks of incubation period, onset is slow, and about 1/3 case is asymptomatic.Form with arm-bronchitis, pneumonia, ear drum membrane inflammation etc. occurs, and the heaviest with pneumonia.That morbidity just has is weak, headache, pharyngalgia, feel cold, heating, muscular soreness, loss of appetite, feel sick, vomiting etc., headache is significantly.The heating height differs, can be up to 39 ℃.Occur tangible respiratory symptom after 2～3 days,, cough a small amount of sticking expectorant or mucopurulent sputum, sputum mixed with blood sometimes as the paroxysmal irritable cough.Generate heat sustainable 2～3 weeks.Temperature still can have been lost cough after recovering normally, pain under companion's breastbone, but do not have chest pain.Higher with children's and middle-aged and elderly people sickness rate.At present both at home and abroad to the Drug therapy of primary disease, have following problem: (1) mainly uses antibiotic, but the pneumonia that variant virus is caused is often powerless; (2) easily produce drug resistance.
Summary of the invention
The object of the present invention is to provide a kind of medicine with prevention and treatment pneumonia, bronchitis, pharyngitis and upper respiratory tract infection.
Another object of the present invention provides the preparation method of this prevention and treatment pneumonia, bronchitis, pharyngitis and upper respiratory tract infection.
Solution of the present invention is based on motherland's medical science all belongs to the Epidemic Febrile Disease scope to diseases such as pneumonia, bronchitis, pharyngitis, upper respiratory tract infection understanding and Therapeutic Principle.The cause of disease is a warm pathogen tend to attack the upper orifices, goes into attacking the lung first from mouth and nose.From the beginning of mainly showing as fever without perspiration, or have antiperspirant not smooth, micro evil wind is cold, and it is thirsty have a headache, the pharyngalgia of coughing, and it is unfavorable to cough up phlegm, red tip of the tongue, white and thin fur or BOHUANG, floating and rapid pulse.Pathogenesis always belongs to wind heat and attacks lung qi obstruction outward.Control suitable heat-clearing and toxic substances removing, relieving the exterior syndrome with drugs of pungent in flavor and cool in nature, lung qi dispersing cough-relieving.The present invention sincerely abides by " interior warp " " wind is excessive in interior, controls with hot cool, and assistant is with sweetness and bitterness ".Leaf sky scholar is said: " can be also what defend antiperspirant ".Wu brings up logical also proposition: " controlling the part of the body cavity above the diaphragm housing the heart and lungs such as plumage, non-light erectile problem ".Flos Lonicerae, Fructus Forsythiae are monarch drug, and the cool completely effect of evil heat clearing away of existing suffering is had the merit of repelling foulness with aromatics detoxifcation again.Ministerial drug has following 3 groups, Radix Platycodonis, the hot flat lung moistening of Rhizoma Belamcandae, analgesic eliminating stagnation, lung qi dispersing sore-throat relieving; Lung being a delicate viscus, happiness is respectful clearly, and wind heat is attacked lung and cold-resistant hot, and refining liquid is expectorant, Fructus Arctii, Bulbus Fritillariae Cirrhosae, Herba Houttuyniae, clearing heat and moistening lung, preventing phlegm from forming and stopping coughing, the pent-up of opening mental disorder, the numbness plug of logical chest and diaphragm; Radix Scutellariae, Radix Isatidis heat-clearing and toxic substances removing, expel the heat-evil in outside.The Rhizoma Anemarrhenae, Radix Glycyrrhizae clearing away heat and nourishing YIN, both solar heat protection poisoned dry impairment of YIN, can restrict bitter and cold medicines damage gastric qis such as Radix Isatidis, Radix Scutellariae again, was to be adjuvant drug.The Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription is with being messenger drug.So can make battalion defend mediation, the space between skin and muscles using pungent drugs for dispersion and bitter drugs for purgation, hot detoxicating is separated, and expectorant disappears to cough and ends, and takes a broad view of the full presciption medicine thing and forms, and integrates heat-clearing and toxic substances removing, relieving the exterior syndrome with drugs of pungent in flavor and cool in nature, lung qi dispersing cough-relieving.
Medicine of the present invention is to be made by following component: (consumption is a weight portion)
Flos Lonicerae 10-25 Fructus Forsythiae 5-15 Radix Scutellariae 5-15 Radix Isatidis 5-15
Rhizoma Belamcandae 5-10 Radix Platycodonis 5-10 Herba Houttuyniae 10-20 Fructus Arctii 5-15
Bulbus Fritillariae Cirrhosae 10-20 Rhizoma Anemarrhenae 5-15 Radix Glycyrrhizae 2-10.
Formula optimization weight (part) ratio range of preparation medicine of the present invention is:
Flos Lonicerae 12-25 Fructus Forsythiae 10-15 Radix Scutellariae 10-15 Radix Isatidis 6-10
Rhizoma Belamcandae 6-10 Radix Platycodonis 6-10 Herba Houttuyniae 12-20 Fructus Arctii 5-10
Bulbus Fritillariae Cirrhosae 10-15 Rhizoma Anemarrhenae 5-10 Radix Glycyrrhizae 2-5.
The optimum weight of medicine of the present invention (part) proportioning is:
Flos Lonicerae 12 Fructus Forsythiaes 10 Radix Scutellariaes 10 Radix Isatidis 6
Rhizoma Belamcandae 6 Radix Platycodoniss 6 Herba Houttuyniae 12 Fructus Arctiis 6
Bulbus Fritillariae Cirrhosae 10 Rhizoma Anemarrhenaes 10 Radix Glycyrrhizaes 3.
The above-mentioned medicine that is used to prevent and treat pneumonia, bronchitis, pharyngitis and upper respiratory tract infection can be made said multiple dosage form on the pharmaceutics, as oral liquid, capsule or tablet.
The method that above-mentioned each component is made medicine of the present invention is:
Flos Lonicerae, Fructus Forsythiae are extracted volatile oil, and the aqueous solution after distillation device is in addition collected; Medicinal residues after the distillation and all the other each flavors decoct with water three times, and collecting decoction filters, and filtrate and above-mentioned aqueous solution merge, concentrate, room temperature to be chilled to, adding ethanol, to make content be 65%, stirs evenly, after leaving standstill, go supernatant to reclaim ethanol, being concentrated into relative density is 1.10～1.15, and concentrated solution merges with volatile oil again, add correctives, regulate pH value, add water again to prescribed limit, stir evenly, leave standstill, filter, sterilization, fill makes oral liquid.
The oral liquid of making adds proper adjuvant through after concentrating, and can be made into capsule or tablet.
An important feature of the present invention is to contain the multiple composition that can improve the human body body's immunity in the medicament, and effective mediator's body immunity function improves the ability of human body self resist the disease.
Clinical drug of the present invention uses the result to show to have following advantage:
What (1) the present invention selected for use is to be raw material with the plant amedica, and each component meets the pharmaceutical control law regulation.Utilize the comprehensive function treatment of the Chinese medicine of respectively distinguishing the flavor of, nontoxic to human body.
(2) the present invention not only can prevent and treat pneumonia, bronchitis, pharyngitis, upper respiratory tract infection etc. to the ill, improves the effect of human body self immunologic function in addition, plays the effect for the treatment of both the principal and secondary aspects of a disease.
For the therapeutic effect of medicine of the present invention is described, at first done animal pharmacodynamics experimentation, the result is as follows: 1 oral liquid of the present invention (hereinafter to be referred as JFY) influences 1.1 JFY to the viral pneumonia immune function of mice influence of immune factor level in FM1 (influenza virus Mus lung adapted strain) the strain virus infecting mouse blood plasma be the results are shown in Table 1
Table 1 JFY is to the influence of IL-1, IL-2, TNF-alpha levels in the mice plasma (x ± s)
| Group | ????n | A value (570nm) | ||
| ????IL-1 | ????IL-2 | ????TNF-α | ||
| Normal group | ????12 | ?0.933±0.056 | ?0.668±0.031 | ?0.040±0.015 |
| Infected group | ????12 | ?0.866±0.051△ | ?0.655±0.041 | ?0.068±0.017△ |
| The virazole group | ????12 | ?0.884±0.047 | ?0.652±0.045 | ?0.052±0.024* |
| The JFY small dose group | ????12 | ?0.906±0.048 | ?0.688±0.061* | ?0.046±0.018* |
| The heavy dose of group of JFY | ????12 | ?0.918±0.039 | ?0.713±0.036**△ | ?0.042±0.010** |
Annotate: compare △ P＜0.01 with normal group; Compare * P＜0.05 with the mould infected group of disease; * P＜0.01;
Table 1 is the result show, in the viral pneumonia process, the IL-2 level has reduction trend due to the influenza virus FM1 infecting mouse, and the even generation that can promote IL-2 in the blood plasma of the large and small dosage group of JFY, virazole does not have obvious influence to IL-2 level in the blood plasma.Infection group and viral infection group mice plasma IL-1 level reduces (P＜0.05), and the IL-1 level is on the rise after the JFY treatment, but compares not statistically significant P＞0.05 with infected group.The TNF-alpha content increases (P＜0.05) in the viral infection matched group blood plasma, and JFY can significantly reduce TNF-α in the blood plasma, and heavy dose of group of effect is more obvious.1.2 JFY influences table 1 JFY to the influence of INF-γ level in the FM1 virus infected mice blood plasma (x ± s) to INF-γ level in the FM1 virus infected mice blood plasma
| Group | ????n | A value (750nm) |
| Normal group | ????12 | ????0.298±0.028 |
| Infected group | ????12 | ????0.164±0.029△ |
| The virazole group | ????12 | ????0.357±0.069 ** |
| The JFY small dose group | ????12 | ????0.342±0.596 ** |
| The heavy dose of group of JFY | ????12 | ????0.322±0.030 ** |
Annotate: organize comparison △ P＜0.01 with the intact animal; * and infection group and viral infection group relatively P＜0.01 as can be seen from Table 1, due to the influenza infection mice in the blood plasma of viral pneumonia INF-γ level reduce (P＜0.01), after the JFY treatment, the level of INF-γ all significantly raises in the big small dose group blood plasma.2 JFY at experimentation 2.1 JFY of external inhibitory anti-virus to 9 kinds of pathogenic bacterium extracorporeal bacteria inhibitor tests
Table 1 JFY is to 9 kinds of pathogenic bacterium extracorporeal bacteria inhibitor test results
Annotate: from No. 6 pipes of No. 1 pipe to the liquor strength is the series concentration of twice dilution, and its concentration is respectively " 1 ": 0.5ml/ml; " 2 ": 0.25ml/ml; " 3 ": 0.125ml/ml; " 4 ": 0.0625ml/ml; " 5 ": 0.0313ml/ml; " 6 ": 0.0156ml/ml.In every milliliter of medicinal liquid this life medicine total amount 1 gram.No. 7 pipe is a positive control, manages negative control tube No. 8.
| Experimental strain | Test tube number | |||||||
| ?1 | ????2 | ??3 | ??4 | ??5 | ??6 | ??7 | ??8 | |
| Staphylococcus aureus | ?- | ????- | ??- | ??+ | ??+ | ??+ | ??+ | ??- |
| Beta hemolytic streptococcus | ?- | ????- | ??- | ??- | ??+ | ??+ | ??+ | ??- |
| Diplococcus pneumoniae | ?- | ????- | ??- | ??- | ??+ | ??+ | ??+ | ??- |
| Hemophilus influenza | ?- | ????- | ??+ | ??+ | ??+ | ??+ | ??+ | ??- |
| Jia Xingrongxuexinglianqiujun | ?- | ????- | ??- | ??- | ??+ | ??+ | ??+ | ??- |
| Pseudomonas aeruginosa | ?- | ????- | ??- | ??- | ??+ | ??+ | ??+ | ??- |
| Escherichia coli | ?- | ????- | ??- | ??+ | ??+ | ??+ | ??+ | ??- |
| Staphylococcus albus | ?- | ????- | ??- | ??+ | ??+ | ??+ | ??+ | ??- |
| Bacillus proteus | ?- | ????- | ??+ | ??+ | ??+ | ??+ | ??+ | ??- |
Experimental result shows, the MIB of 9 kinds of bacterium being done, and JFY is stronger to the external bacteriostatic activity of beta hemolytic streptococcus, Diplococcus pneumoniae, Jia Xingrongxuexinglianqiujun and pseudomonas aeruginosa, and MIB is 0.0625ml/ml; Escherichia coli, Staphylococcus albus staphylococcus aureus are had certain bacteriostasis, and MIB is 0.125ml/m1; The bacteriostatic activity of Bacillus proteus and stream bar bacillus is weak (MIB is 0.25ml/m1).3 JFY and virazole the results are shown in Table 1 to inhibitory action experimentation 3.1 JFY of SRV (respiratory syncytial virus) and virazole to the inhibitory action of SRV
Table 1 JFY and virazole are to the inhibitory action result of SRV
| Grouping | Dosage | Every hole CPE degree | Average CPE | CPE suppression ratio (%) |
| Sharp lung oral liquid detoxifies | ????5 | ????0000 | ????0.00 | ????100.00 |
| ????2.5 | ????1111 | ????1.00 | ????90.00 | |
| ????1.25 | ????4111 | ????1.75 | ????68.75 | |
| ????0.63 | ????1233 | ????2.25 | ????42.86 | |
| ????0.31 | ????1234 | ????2.50 | ????21.05 | |
| ????0.16 | ????3434 | ????3.50 | ????4.35 | |
| ????0.08 | ????4444 | ????4.00 | ????0.00 | |
| Virazole | ????12.50 | ????1111 | ????1.00 | ????87.88 |
| ????6.25 | ????2333 | ????2.75 | ????53.13 | |
| ????3.13 | ????3333 | ????3.00 | ????30.77 | |
| ????1.56 | ????2444 | ????3.50 | ????16.33 | |
| ????0.78 | ????3344 | ????3.50 | ????9.84 | |
| ????0.39 | ????2444 | ????3.50 | ????5.48 |
| ????0.20 | ????3344 | ????3.50 | ????2.78 | |
| ????0.10 | ????4444 | ????4.00 | ????0.00 | |
| Normal control | ????0000 | ????0.00 | ????100.00 | |
| Virus control | ????4444 | ????4.00 | ????0.00 |
Suppress viral aspect according to the gained data, the TC50 of JFY and virazole is respectively 25.98mg/ml, 76.43ug/ml, the cytopathy degree of each dosage group of Kruskal Wallis method of inspection comparative drug and virus control group, the result shows, JFY 5,2.5,1.25,0.625mg/ml dosage group, virazole 12.5,6.25,3.125ug/ml dosage group all have obvious inhibitory action (P＜0.01) to RSV (respiratory syncytial virus).Adopt Reed Muench method to calculate, the EC50 of JFY is 0.758mg/ml, and TI is 34.29; The EC50 of virazole is 5.672ug/ml, and TI is 13.47.4 JFY cough-relievings, reduce phlegm, antiasthmatic effect experimentation 4.1 JFY draw the antitussive action experimentation of coughing to mice ammonia
Table 1 JFY draws the antitussive action coughed (x ± S) to mice ammonia
| Group | ????n | Cough latent period (s) | Cough number of times (3min) |
| Model control group | ????12 | ????50.90±9.46 | ????49.20±14.45 |
| The JIZHI TANGJIANG group | ????12 | ????72.00±20.38 * | ????25.80±6.68 * |
| The JFY small dose group | ????12 | ????90.50±24.45 ** | ????18.10±10.74 ** |
| The heavy dose of group of JFY | ????12 | ????100.50±15.92 ** | ????16.70±5.66 ** |
Annotate: compare * P＜0.05 with model control group; * P＜0.01; 4.2 JFY is to the resolve phlegm effect experimentation of mice
Table 1 JFY is to the resolve phlegm effect of mice (x ± S)
Annotate: compare * P＜0.05 with model control group; * P＜0.01; Compare △ P＜0.05 with the JIZHI TANGJIANG group;
| Group | ???n | The phenol red excretion amount of trachea (OD value) |
| Model control group | ??12 | ????0.061±0.026 |
| The JIZHI TANGJIANG group | ??12 | ????0.101±0.056 * |
| Small dose group | ??12 | ????0.147±0.062 **△ |
| Heavy dose of group | ??12 | ????0.152±0.031 **△ |
Table 2 JFY is to rat expectoration amount effect (x ± S)
| Group | ????n | Row's Yan amount (mL/h) | |
| Before the administration | After the administration | ||
| The normal control group | ????12 | ????44.2±10.0 | ????47.4±9.5 |
| JIZHI TANGJIANG | ????12 | ????48.1±13.0 | ????83.4±32.5 * |
| The JFY small dose group | ????12 | ????47.9±10.6 | ????91.2±41.2 ** |
| The heavy dose of group of JFY | ????12 | ????46.2±15.3 | ????97.9±19.8 ** |
Annotate: compare with the normal control group
*P＜0.05,
*P＜0.01; 4.3 JFY is to the experimentation of Cavia porcellus antiasthmatic effect
Table 1 JFY is to Cavia porcellus antiasthmatic effect (x ± S)
| Group | ????n | Cause and breathe heavily incubation period (S) |
| Model control group | ????8 | ????55.12±29.24 |
| JIZHI TANGJIANG | ????8 | ????78.75±14.98 * |
| The JFY small dose group | ????8 | ????92.12±13.28 **△ |
| The heavy dose of group of JFY | ????8 | ????104.00±14.76 **△ |
Annotate: compare with model control group
*P＜0.05;
*P＜0.01; Compare the experimentation that △ P＜0.04.4 JFY xylol causes the mice auricle swelling influence with the JIZHI TANGJIANG group
Table 1 JFY (be called for short JFY) xylol causes the influence (x ± S) of mice auricle swelling
| Group | ????n | Swelling degree (mg) | Suppression ratio (%) |
| Matched group | ????12 | ????18.7±6.07 | |
| JIZHI TANGJIANG | ????12 | ????13.1±4.01 | ????29.9 * |
| The JFY small dose group | ????12 | ????10.8±3.79 | ????42.2 ** |
| The heavy dose of group of JFY | ????12 | ????9.8±3.85 | ????47.6 ** |
Annotate: compare * P＜0.05 with model control group; * P＜0.01;
More than the result of experimentation of five tables show that the cough that JFY causes the mice chemical stimulation has the obvious suppression effect; Can increase the phenol red excretion amount of mice trachea section, can increase the respiratory tract secretory function, obvious phlegm-dispelling functions is arranged; Can obviously suppress by Cavia porcellus asthma reaction due to 2% acecoline and the 0.1% histamine phosphate's isometric(al) mixed liquor; The mice inflammatory model there is to a certain degree inhibitory action.5 resisiting influenza virus effect experimentatioies, 5.1 JFY are to the experimentation of the dead protective effect of influenza virus infecting mouse
Table 1 JFY is to the protective effect of influenza virus infecting mouse death
Annotate: with the virus control group than * P＜0.05, * * P＜0.01, * * * P＜0.001, with the JIZHI TANGJIANG group than △ P＜0.05.5.2 JFY is to the experimentation of influenza virus mice infected lung index influence
| Group | Number of animals (n) | Death toll | Mortality rate (%) |
| Normal control | ????18 | ????0 | ????0.00 |
| Virus control | ????18 | ????17 | ????94.45 |
| Virazole | ????18 | ????0 | ????0.00 *** |
| JIZHI TANGJIANG | ????18 | ????14 | ????77.78 * |
| The JFY low dose | ????18 | ????9 | ????50.00 **△ |
| The JFY heavy dose | ????18 | ????8 | ????44.44 **△ |
Table 1 JFY is to the exponential influence of influenza virus mice infected lung
Annotate: with the virus control group than * P＜0.05, * * P＜0.01, with the JIZHI TANGJIANG group than △ P＜0.05.5.3 the susceptible toxicity pneumonia of JFY convection current mouse lung is organized the experimentation of blood clotting titre influence
| Group | Number of animals (n) | Lung fat numerical value (x ± s) | Suppression ratio (%) |
| Normal control | ????18 | ????0.468±0.132 | ????- |
| Virus control | ????18 | ????1.213±0.308 | ????- |
| Virazole | ????18 | ????1.104±0.326 | ????8.99 |
| JIZHI TANGJIANG | ????18 | ????0.896±0.204 | ????26.13 * |
| The JFY low dose | ????18 | ????0.758±0.286 | ????37.51 ** |
| The JFY heavy dose | ????18 | ????0.726±0.326 | ????40.15 **△ |
The susceptible toxicity pneumonia of table 1 JFY convection current mouse lung is organized the influence of blood clotting titre
| Group | Number of animals (n) | The blood clotting titre | |
| ????(x±s) | ????log(x±s) | ||
| Normal control | ????18 | ????- | ????- |
| Virus control | ????18 | ????21.10±1.84 | ????1.3036±0.2739 |
| Virazole | ????18 | ????2.28±1.67 | ????0.321±0.004 *** |
| JIZHI TANGJIANG | ????18 | ????11.78±2.05 | ????1.1104±0.3726 * |
| The JFY low dose | ????18 | ????8.43±1.71 | ????1.0977±0.2817 ** |
| The JFY heavy dose | ????18 | ????6.15±1.73 | ????0.8122±0.3108 ** |
More than the experimental datas of 3 tables show: JFY has obvious protective effect to the virus mice that causes death; Can reduce the lung index of influenza infection mice; Can obviously reduce the mouse lung that is contaminted and organize the viral hemoagglutination titre.
For checking medicine of the present invention pneumonia, bronchitis, pharyngitis, upper respiratory tract infection are treated preventive effect, the present invention is through the clinical observation of 295 routine systems, and case is from Guangzhou General Hospital Guangzhou Military Command's general medicine, Respiratory Medicine, emergency treatment and outpatient service etc.Viral pneumonia group 33 examples wherein, male 14 examples, women 19 examples, big 66 years old age, 36.6 ± 4.22 years old mean age, matched group 28 examples, male 20 examples, women 8 examples, 10～70 years old age, average 42 ± 2.3 years old; Acute bronchitis 56 examples, male 30 examples, women 26 examples, minimal ages 16 years old, maximum 68 years old age; Average 38 ± 2.8 years old, matched group 48 examples, male 22 examples, women 26 examples, minimal ages 8 years old, maximum 52 years old age, average 38 ± 4.2 years old; Upper respiratory tract infection group 88 examples, male 42 examples, women 46 examples, minimal ages 16 years old, maximum 68 years old, 48.6 ± 3.6 years old mean age, matched group 44 examples, male 20 examples, women 24 examples, 10～70 years old age, average 56 ± 3.2 years old.Two groups similar substantially at aspects such as sex, age, the course of disease, symptom, sign, lab testings, has comparability (P＞0.05).
Instructions of taking: oral, 3 times on the one, one time 1.Children's is cut down according to the circumstance.This product is put for a long time can have trace muddy, faces with preceding jolting to get final product.Clinical test results such as table 1,2 and table 3.
Table 1 JFY analyzes the treatment clinical observation result of viral pneumonia
| Grouping | Recovery from illness (routine number) | Produce effects (routine number) | Effectively (routine number) | Invalid (routine number) | ??X 2Value | The P value |
| The viral pneumonia group | 22(66％) | ???8(24％) | ??2(0.6％) | ???1(0.03％) | ??7.944 | ??0.047 |
| Matched group (SHUANGHUANLIAN) | 10(35.7％) | ???8(28.6％) | ??6(21.4％) | ???4(14.3％) |
Table 2 JFY analyzes the treatment clinical observation result of acute bronchitis
| Grouping | Recovery from illness (routine number) | Produce effects (routine number) | Effectively (routine number) | Invalid (routine number) | ??X 2Value | The P value |
| The acute bronchitis group | 38(67.9％) | ?12(21.4％) | 4(7.1％) | 2(3.6％) | ??9.599 | ??0.022 |
| Matched group (SHUANGHUANLIAN) | 20(41.7％) | ?12(25.0％) | 10(20.8％) | 6(12.5％) |
Table 3 JFY analyzes the Treatment of Upper Respiratory Tract Infection clinical observation result
| Grouping | Recovery from illness (routine number) | Produce effects (routine number) | Effectively (routine number) | Invalid (routine number) | ??X 2Value | The P value |
| The upper respiratory tract infection group | 66(75.0％) | ?13(14.8％) | ???7(8％) | ??2(2.3％) | ??8.845 | ??0.031 |
| Matched group (JIZHI TANGJIANG) | 23(52.3％) | ?10(22.7％) | ???6(13.6％) | ??5(11.4％) |
Show that from the result of above 3 tables JFY is slightly better than SHUANGHUANLIAN commonly used and JIZHI TANGJIANG effect to viral pneumonia, acute bronchitis and Treatment of Upper Respiratory Tract Infection.
Embodiment 1 takes by weighing raw material (gram) by following proportioning
Flos Lonicerae 12 Fructus Forsythiaes 10 Radix Scutellariaes 10 Radix Isatidis 6
Rhizoma Belamcandae 6 Radix Platycodoniss 6 Herba Houttuyniae 12 Fructus Arctiis 6
Bulbus Fritillariae Cirrhosae 10 Rhizoma Anemarrhenaes 10 Radix Glycyrrhizaes 3 production methods are as follows: above 11 flavors, Flos Lonicerae, Fructus Forsythiae are extracted volatile oil, and the aqueous solution after distillation device is in addition collected; Medicinal residues after the distillation and all the other each flavors decoct with water three times, and each 1 hour, collecting decoction filtered.Filtrate and above-mentioned aqueous solution merge, and concentrate room temperature to be chilled to, adding ethanol, to make content be 65%, stirs evenly, after leaving standstill, go supernatant to reclaim ethanol, being concentrated into relative density is 1.10～1.15 (90～95 ℃), and concentrated solution merges with volatile oil again, add correctives, regulate pH value, add water to 1000ml again to prescribed limit, stir evenly, leave standstill, filter, fill, sterilization promptly gets oral liquid.
Embodiment 2 takes by weighing raw material (gram) by following proportioning
Flos Lonicerae 15 Fructus Forsythiaes 12 Radix Scutellariaes 12 Radix Isatidis 8
Rhizoma Belamcandae 8 Radix Platycodoniss 8 Herba Houttuyniae 15 Fructus Arctiis 8
Bulbus Fritillariae Cirrhosae 12 Rhizoma Anemarrhenaes 8 Radix Glycyrrhizaes 5 production methods are as follows: above 11 flavors, Flos Lonicerae, Fructus Forsythiae are extracted volatile oil, and the aqueous solution after distillation device is in addition collected; Medicinal residues after the distillation and all the other each flavors decoct with water three times, and each 1 hour, collecting decoction filtered.Filtrate and above-mentioned aqueous solution merge, and concentrate room temperature to be chilled to, adding ethanol, to make content be 65%, stirs evenly, after leaving standstill, go supernatant to reclaim ethanol, being concentrated into relative density is 1.10～1.15 (90～95 ℃), and concentrated solution merges with volatile oil again, add correctives, regulate pH value, add water to 1000ml again to prescribed limit, stir evenly, leave standstill, filter, concentrate, add proper adjuvant, make tablet.
Claims (6)
1, the medicine of a kind of prevention and treatment pneumonia, bronchitis, pharyngitis and upper respiratory tract infection is characterized in that it is the medicament of being made by the following weight proportion raw material:
Flos Lonicerae 10～25 Fructus Forsythiaes 5～15 Radix Scutellariaes 5～15 Radix Isatidis 5～15
Rhizoma Belamcandae 5～10 Radix Platycodoniss 5～10 Herba Houttuyniae 10～20 Fructus Arctiis 5～15
Bulbus Fritillariae Cirrhosae 10～20 Rhizoma Anemarrhenaes 5～15 Radix Glycyrrhizaes 2～10.
2, the medicine of prevention according to claim 1 and treatment pneumonia, bronchitis, pharyngitis and upper respiratory tract infection, wherein the weight proportion of each raw material is:
Flos Lonicerae 12～25 Fructus Forsythiaes 10～15 Radix Scutellariaes 10～15 Radix Isatidis 6～10
Rhizoma Belamcandae 6～10 Radix Platycodoniss 6～10 Herba Houttuyniae 12～20 Fructus Arctiis 5～10
Bulbus Fritillariae Cirrhosae 10～15 Rhizoma Anemarrhenaes 5～10 Radix Glycyrrhizaes 2～5.
3, the medicine of prevention according to claim 1 and treatment pneumonia, bronchitis, pharyngitis and upper respiratory tract infection, wherein the weight proportion of each raw material is:
Flos Lonicerae 12 Fructus Forsythiaes 10 Radix Scutellariaes 10 Radix Isatidis 6
Rhizoma Belamcandae 6 Radix Platycodoniss 6 Herba Houttuyniae 12 Fructus Arctiis 6
Bulbus Fritillariae Cirrhosae 10 Rhizoma Anemarrhenaes 10 Radix Glycyrrhizaes 3.
4, according to the medicine of claim 1,2 or 3 described preventions and treatment pneumonia, bronchitis, pharyngitis and upper respiratory tract infection, it is characterized in that said medicament is a said dosage form on any pharmaceutics.
5, the medicine of prevention according to claim 4 and treatment pneumonia, bronchitis, pharyngitis and upper respiratory tract infection is characterized in that said medicament is oral liquid, capsule or tablet.
6, the preparation method of the medicine of the described prevention of claim 5 and treatment pneumonia, bronchitis, pharyngitis and upper respiratory tract infection is characterized in that Flos Lonicerae, Fructus Forsythiae are extracted volatile oil, and the aqueous solution after distillation device is in addition collected; Medicinal residues after the distillation and all the other each flavors decoct with water three times, and collecting decoction filters, and filtrate and above-mentioned aqueous solution merge, concentrate, room temperature to be chilled to, adding ethanol, to make content be 65%, stirs evenly, after leaving standstill, go supernatant to reclaim ethanol, being concentrated into relative density is 1.10～1.15, and concentrated solution merges with volatile oil again, add correctives, regulate pH value, add water again to prescribed limit, stir evenly, leave standstill, filter, sterilization, fill makes oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03139769 CN1221277C (en) | 2003-07-09 | 2003-07-09 | Prophylaxis medication for treating pneumonia, bronchitis, pharyngitis and upper respiratory tract infection as well as its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03139769 CN1221277C (en) | 2003-07-09 | 2003-07-09 | Prophylaxis medication for treating pneumonia, bronchitis, pharyngitis and upper respiratory tract infection as well as its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1480191A true CN1480191A (en) | 2004-03-10 |
| CN1221277C CN1221277C (en) | 2005-10-05 |
Family
ID=34155089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03139769 Expired - Fee Related CN1221277C (en) | 2003-07-09 | 2003-07-09 | Prophylaxis medication for treating pneumonia, bronchitis, pharyngitis and upper respiratory tract infection as well as its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1221277C (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1296088C (en) * | 2004-04-30 | 2007-01-24 | 北京中医药大学药厂 | Medicine for treating acute pharyngitis of children and preparation method thereof |
| CN100411644C (en) * | 2006-04-26 | 2008-08-20 | 吉林大学 | Medicine for treating chronic pharyngitis |
| CN101554446B (en) * | 2009-05-20 | 2011-01-12 | 贺业生 | Traditional Chinese medicine composition for treating chronic pharyngitis |
| CN101385825B (en) * | 2008-10-27 | 2011-02-16 | 陈志忠 | Traditional Chinese medicine preparation for preventing and treating cold |
| CN102488778A (en) * | 2011-12-21 | 2012-06-13 | 无锡正大畜禽有限公司 | Chinese traditional medicine preparation for treating upper respiratory tract infection of livestock and preparation method thereof |
| CN103463282A (en) * | 2013-10-09 | 2013-12-25 | 河南中医学院 | Traditional Chinese medicine for treating infectious tracheobroncheitis of broilers |
| CN107714909A (en) * | 2017-10-30 | 2018-02-23 | 谭宗学 | A kind of Chinese medicine composition for treating chronic bronchitis, bronchitis, asthma, pulmonary emphysema and preparation method thereof |
| CN108785559A (en) * | 2018-09-17 | 2018-11-13 | 河南科技大学第附属医院 | A kind of drug and preparation method thereof for treating respiratory tract infection |
| CN111249374A (en) * | 2020-03-16 | 2020-06-09 | 重庆呈品医药有限公司 | Oral liquid for inhibiting and recovering novel coronavirus pneumonia |
| CN111956722A (en) * | 2020-09-10 | 2020-11-20 | 江苏医药职业学院 | Antiviral traditional Chinese medicine composition |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101342331B (en) * | 2008-09-08 | 2011-05-11 | 李娜 | Traditional Chinese medicine for treating pulmonitis and upper respiratory tract infection |
| CN101385828B (en) * | 2008-09-18 | 2011-06-08 | 李爱英 | Traditional Chinese medicine for treating urgent and chronic inflammation of upper respiratory tract |
-
2003
- 2003-07-09 CN CN 03139769 patent/CN1221277C/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1296088C (en) * | 2004-04-30 | 2007-01-24 | 北京中医药大学药厂 | Medicine for treating acute pharyngitis of children and preparation method thereof |
| CN100411644C (en) * | 2006-04-26 | 2008-08-20 | 吉林大学 | Medicine for treating chronic pharyngitis |
| CN101385825B (en) * | 2008-10-27 | 2011-02-16 | 陈志忠 | Traditional Chinese medicine preparation for preventing and treating cold |
| CN101554446B (en) * | 2009-05-20 | 2011-01-12 | 贺业生 | Traditional Chinese medicine composition for treating chronic pharyngitis |
| CN102488778A (en) * | 2011-12-21 | 2012-06-13 | 无锡正大畜禽有限公司 | Chinese traditional medicine preparation for treating upper respiratory tract infection of livestock and preparation method thereof |
| CN103463282A (en) * | 2013-10-09 | 2013-12-25 | 河南中医学院 | Traditional Chinese medicine for treating infectious tracheobroncheitis of broilers |
| CN103463282B (en) * | 2013-10-09 | 2014-12-03 | 河南中医学院 | Traditional Chinese medicine for treating infectious tracheobroncheitis of broilers |
| CN107714909A (en) * | 2017-10-30 | 2018-02-23 | 谭宗学 | A kind of Chinese medicine composition for treating chronic bronchitis, bronchitis, asthma, pulmonary emphysema and preparation method thereof |
| CN108785559A (en) * | 2018-09-17 | 2018-11-13 | 河南科技大学第附属医院 | A kind of drug and preparation method thereof for treating respiratory tract infection |
| CN108785559B (en) * | 2018-09-17 | 2021-07-02 | 河南科技大学第一附属医院 | Medicine for treating respiratory tract infection and preparation method thereof |
| CN111249374A (en) * | 2020-03-16 | 2020-06-09 | 重庆呈品医药有限公司 | Oral liquid for inhibiting and recovering novel coronavirus pneumonia |
| CN111956722A (en) * | 2020-09-10 | 2020-11-20 | 江苏医药职业学院 | Antiviral traditional Chinese medicine composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1221277C (en) | 2005-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100344313C (en) | Chinese patent drug for treating infantile cold and repeated cold, and its prepn. method | |
| CN1221277C (en) | Prophylaxis medication for treating pneumonia, bronchitis, pharyngitis and upper respiratory tract infection as well as its preparing method | |
| CN1210047C (en) | Medicine for treating cold and preparation method thereof | |
| CN1883560A (en) | A compound Chinese medicinal preparation containing Chinese globeflower and method for preparing same | |
| CN102973776A (en) | Chicken respiratory disease prevention and treatment traditional Chinese medicine composition and preparation method thereof | |
| CN103211901B (en) | Lung clearing and inflammation diminishing medicament and preparation method thereof | |
| CN111569035A (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating new coronary pneumonia, especially asymptomatic infected patients | |
| CN101099825A (en) | Lung heat-cleaning throat-moistening cough-relieving syrup | |
| CN105688157A (en) | Traditional Chinese medicine compound preparation for resisting swine influenza virus and preparing method thereof | |
| CN105168848A (en) | Compound buccal tablets prepared from lonicera japonica, Chinese olive, radix platycodi and other traditional Chinese medicines and used for clearing heat from throat | |
| CN111514231A (en) | Application of ephedra and apricot lung-ventilating traditional Chinese medicine composition as influenza virus treatment medicine | |
| CN116139237B (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
| CN113559205B (en) | Traditional Chinese medicine composition for treating infantile common cold and application | |
| CN105535406A (en) | Traditional Chinese medicine composition for preventing and treating livestock respiratory disease | |
| CN1872192A (en) | A medication composition,and preparation method | |
| CN1289124C (en) | Medicine for treating child common cold and its preparation method | |
| CN101411752A (en) | Granular formulation for treating children's pneumonia | |
| CN1229129C (en) | cough-relieving plaster | |
| CN112089799A (en) | Compound preparation for treating chicken bronchial embolism and preparation method thereof | |
| CN105343503B (en) | A kind of pharmaceutical composition that treating sphagitis and its application | |
| CN1291730C (en) | Chinese medicine for preventing and treating SARS virus | |
| CN111514230A (en) | Lung-ventilating and lung-ventilating traditional Chinese medicine capsule containing ephedra and apricot seeds and preparation method of lung-ventilating and lung-ventilating traditional Chinese medicine capsule | |
| CN1261125C (en) | Chinese herbal medicine and for treating acute rhinitis and chronic rhinitis as well as its preparing method | |
| CN1742786A (en) | Chinese medicine for preventing and controlling infants repeated respiratory tract inflammation and producing method | |
| CN104258020A (en) | Traditional Chinese medicine composition for treating pneumonia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU UNIVERSITY OF TRADITIONAL CHINESE MEDIC Free format text: FORMER OWNER: SHI SHIDE Effective date: 20081031 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20081031 Address after: No. 232 East Ring Road, Panyu District University, Guangzhou, Guangdong Patentee after: Guangzhou University of Chinese Medicine Address before: Guangzhou City, Guangdong province Liuhua Road No. 111, Genenral Hospital of PLA Guangzhou Military Area, Department of Medical Laboratory Patentee before: Shi Shide |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051005 Termination date: 20100709 |